MONITORING DEVELOPMENT PROGRESS Sample Clauses

MONITORING DEVELOPMENT PROGRESS. Through planned design reviews and test activities, Iridium, Inc. will be able to monitor the TND progress. Duplication of testing for the purposes of satisfying requirements of the TND should be avoided. Iridium, Inc. will be afforded the opportunity to attend Gateway Design Reviews and participate in TND testing as described below. The test objectives of the TND contract include verification through test and demonstration that the IRIDIUM Gateway Equipment design meets the Functional Objectives identified in Section 3.1, the Performance Objectives outlined in Section 3.2 and as identified in Appendix A, the services described in Appendix B and the OA&M capabilities listed in Appendix C. The integrated Gateway Equipment will be shown to function as an integral part of the IRIDIUM Communication System. To accomplish the objectives, testing will be performed at four levels. The first testing level is subsystem acceptance testing. This testing will be performed to verify that the suppliers have met the subsystem level requirements. The second level of testing is performed at the Gateway Equipment level by integrating and testing the subsystems together as a functional entity. This level of testing will be performed to verify that the Gateway segment level requirements have been met and all interfaces external to the Gateway have been verified. Simulation will be used for most external interfaces. The third level of testing demonstrates the Gateway Equipment in the Gateway test laboratory. This level of testing introduces other system elements such as the System Control Segment Control Facility, the Message Termination Controller, and the ISU, which replace simulators in the Gateway test laboratory. The objective of this testing is to integrate the Gateway segment into the IRIDIUM Communications System in a laboratory environment. The fourth and final level of testing will be performed to demonstrate the integrated ---------------------------------- * Information has been omitted and filed separately with the Commission pursuant to Rule 406 of the Securities Act of 1933. By its Order Granting Approval pursuant to Rule 406, dated June 9, 1997, the Commission granted confidential treatment. Gateway Equipment functions in the IRIDIUM Communications System using on-orbit satellites as available. *
AutoNDA by SimpleDocs
MONITORING DEVELOPMENT PROGRESS. Through planned design reviews and test activities, Iridium, Inc. will be able to monitor the TND progress. Duplication of testing for the purposes of satisfying requirements of the TND should be avoided. Iridium, Inc. will be afforded the opportunity to attend Gateway Design Reviews and participate in TND testing as described below. The test objectives of the TND contract include verification through test and demonstration that the IRIDIUM Gateway Equipment design meets the Functional Objectives identified in Section 3.1, the Performance Objectives outlined in Section 3.2 and as identified in Appendix A, the services described in Appendix B and the OA&M capabilities listed in Appendix C. The integrated Gateway Equipment will be shown to function as an integral part of the IRIDIUM Communication System. To accomplish the objectives, testing will be performed at four levels. The first testing level is subsystem acceptance testing. This testing will be performed to verify that the ---------------------------------- * Information has been omitted and filed separately with the Commission pursuant to Rule 406 of the Securities Act of 1933.

Related to MONITORING DEVELOPMENT PROGRESS

  • Development Program A. Development Activities to be Undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Information Systems Acquisition Development and Maintenance a. Client Data – Client Data will only be used by State Street for the purposes specified in this Agreement.

  • Initial Development Plan Not later than the Effective Date, Licensee shall have provided Merck with an initial Development plan for the Licensed Product in the Field in the Territory, which shall be incorporated as part of this Agreement as Attachment 3.02(a) (as may be amended in accordance with this Agreement, the “Development Plan”). **CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  • Development Activities NovaDel shall not be required to commence any Development Activities until Licensee has paid at least twenty-five percent (25%) of the non-refundable License Fee described in Section 4.4.

  • Development Work Do, or cause to be done, such development and other work as may be reasonably necessary to protect from diminution and production capacity of the Mortgaged Property and each producing well thereon.

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • Development Plan As defined in Section 3.2(a).

  • Development Plans 4.3.1 For each Licensed Indication and corresponding Licensed Product in the Field, Licensee will prepare and deliver to Licensor a development plan and budget (each a “Development Plan”). The initial Development Plans for each Licensed Indication will be delivered within […***…] after the Grant Date for such Licensed Indication.

  • Research Program Funding 3.1.1 Pfizer will fund the research to be performed by Rigel, pursuant to the Agreement, according to the following schedule: COMMITMENT YEAR ANNUAL COMMITMENT 1 $2,350,000.00 2 $2,350,000.00 The funding payments of two million three hundred and fifty thousand dollars ($2,350,000.00) shall support the work of the equivalent of ten (10) full time employees ("FTEs") of Rigel.

  • Development Diligence Pfizer will use its Commercially Reasonable Efforts to Develop and seek Regulatory Approval for [ * ] Product [ * ] in the Field [ * ]. Pfizer will [ * ] with respect to the Development or Regulatory Approval of Products under this Agreement.

Time is Money Join Law Insider Premium to draft better contracts faster.